araag2/HINT huggingface dataset:
Clinical trial NCT01387230 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: gsk573719, gsk573719
SMILES: OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of COPD

          -  10 pack-year or greater history of cigarette smoking

          -  Post-bronchodilator FEV1/FVC of <0.7

          -  Predicted FEV1 of 70% of normal or less

          -  Modified Medical Research Council (mMRC) dyspnea score of 2 or greater

        Exclusion Criteria:

          -  Women who are pregnant, lactating, or planning to become pregnant

          -  Respiratory disorders other than COPD, including a current diagnosis of asthma

          -  Clinically significant non-respiratory diseases or abnormalities that are not
             adequately controlled

          -  Significant allergy or hypersensitivity to anticholinergics, beta2-agonists, or the
             excipients of magnesium stereate or lactose used in the inhaler delivery device

          -  Hospitalization for COPD or pneumonia within 12 weeks prior to screening

          -  Lung volume reduction surgery within 12 weeks prior to screening

          -  Abnormal and clinically significant ECG findings at screening

          -  Clinically significant laboratory findings at screening

          -  Use of systemic corticosteroids, antibiotics for respiratory tract infections, high
             dose inhaled steroids (>1000mcg fluticasone propionate or equivalent), PDE4
             inhibitors, tiotropium, oral beta2-agoinists, short- and long-acting inhaled
             beta2-agonists, inhaled sodium cromoglycate or nedocromil sodium, or investigational
             medicines for defined time periods prior to the screening visit

          -  Use of long-term oxygen therapy (12 hours or greater per day)

          -  Regular use of nebulized treatment with short-acting bronchodilators

          -  Participation in the acute phase of a pulmonary rehabilitation program

          -  A know or suspected history of alcohol or drug abuse

          -  Affiliation with the investigational site

          -  Previous use of GSK573719 or the combination of GSK573719/GW642444
Clinical trial NCT00060476 (phase 3, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: rofecoxib, comparator: placebo (unspecified)
SMILES: CS(=O)(=O)C1=CC=C(C=C1)C1=C(C(=O)OC1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Regular PSA testing and study biopsies required.
Clinical trial NCT01512108 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: liraglutide, oral anti-diabetic drug
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities (trial-related
             activities are any procedures that would not have been performed during normal
             management of the subject.)

          -  Japanese subjects with type 2 diabetes on monotherapy with an OAD (either glinide,
             metformin, a-glucosidase inhibitor or thiazolidinedione) within approved Japanese
             labelling in addition to diet and exercise therapy. Total daily dose and type of drug
             should have remained unchanged for at least 8 weeks prior to Visit 1

          -  Type 2 diabetes mellitus (clinically diagnosed) for at least 6 months

          -  HbA1c between 7.0-10.0% (both inclusive)

          -  Body Mass Index (BMI) below 40.0 kg/m^2

          -  Outpatients who have no plans for an educational hospitalisation for the purpose of
             glycaemic control. However, hospitalisation for training of self-injection from Visit
             2 that is for no longer than one week is allowed

          -  Subjects able and willing to perform self-monitoring of plasma glucose (SMPG)

        Exclusion Criteria:

          -  Subjects with known or previous malignant tumor and are strongly suspected of
             recurrence (except basal cell skin cancer or squamous cell skin cancer)

          -  Calcitonin above or equal to 160 pg/mL

          -  Personal history of non-familial medullary thyroid carcinoma

          -  Family or personal history of multiple endocrine neoplasia type 2 (MEN-2) or familial
             medullary thyroid carcinoma (FMTC)

          -  History of chronic pancreatitis or idiopathic acute pancreatitis

          -  Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last
             12 months) or hypoglycaemic unawareness as judged by the investigator or
             hospitalisation for diabetic ketoacidosis during the previous 6 months

          -  Treatment with GLP-1 receptor agonist or dipeptidyl peptidase 4 (DPP-4) inhibitor
             within 12 weeks prior to Visit 1

          -  Having contraindications to liraglutide and any of the OADs (according to Japanese
             labelling)
Clinical trial NCT00092677 (phase 3, status: completed)
Conditions: aortic stenosis
ICD codes: I06.0, Q25.3, I35.0, I06.2, Q23.0, I35.2
Drugs: ezetimibe (+) simvastatin, comparator: placebo
SMILES: O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Patients aged 45 to 85 with mild abnormalities of the aortic valve as confirmed by an
             echocardiogram.

        Exclusion Criteria:

          -  Patients previously in a trial using the study drug, or currently taking any
             medications that are not allowed in this study.
Clinical trial NCT00310232 (phase 3, status: terminated)
Conditions: non-small-cell lung carcinoma, lung cancer, anemia
ICD codes: D02.20, D02.21, D02.22, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Reason stopped: 
    recommendation of dsmb for safety issue, increased mortality with study drug.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically confirmed non-small cell lung cancer (squamous cell, large cell,
             adenocarcinoma, or some combination of these), with clinical or pathological stage III
             or IV, or recurrent disease; and

          2. Hemoglobin level at or below 120 g/L; and

          3. At least 18 years of age;

        Exclusion Criteria:

          1. Systemic platinum-based chemotherapy for lung cancer during the previous two months or
             planned platinum-based chemotherapy within the next three months;

          2. Patients previously treated with high dose thoracic radiation (>10 fractions), or
             surgery, without objective evidence of disease recurrence;

          3. Planned high dose thoracic radiation therapy (>10 fractions);

          4. A clinically active malignancy, other than the underlying lung cancer which is
             expected to influence QoL;

          5. Expected survival of three months or less;

          6. ECOG Performance status of 3 or 4 (see Appendix D);

          7. Multiple CNS metastasis or a single CNS lesion that does not demonstrate radiographic
             stability (Screening CT of head required only if symptomatic, no radiographic
             follow-up of single resected lesions required);

          8. Blood transfusions within the last 14 days;

          9. Previous use of erythropoietin;

         10. Anemia due to factors other than cancer / radiotherapy (e.g. hemolysis or
             gastrointestinal bleeding);

         11. Evidence of untreated folate or vitamin B12 deficiency;

         12. History of uncontrolled hypertension or diastolic blood pressure greater than 100 mm
             Hg;

         13. History of seizure disorder;

         14. Known hypersensitivity to mammalian cell-derived products, albumin or any component of
             the study drug;

         15. Pregnancy, lactation or parturition within the previous 30 days;

         16. Unwillingness or inability to complete the required QoL questionnaires;

         17. Mental incompetence, including psychiatric or addictive disorders which would preclude
             meaningful completion of questionnaires;

         18. Geographically inaccessible for treatment or follow-up evaluations;

         19. Currently enrolled in an ongoing therapeutic study;
Clinical trial NCT00615251 (phase 3, status: completed)
Conditions: infertility
ICD codes: N46.8, N46.9, N97.9, N97.0, N97.1, N97.2, N97.8
Drugs: dr-2011, crinone 8%
SMILES: [H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Pre-menopausal, aged 18-42 old at time of consent

          -  At least one cycle without fertility medication prior to screening

          -  Tubal, idiopathic, male factor, ovulatory dysfunction or endometriosis- linked
             infertility

          -  Semen analysis (frozen sperm, including donor sperm, may be used, as long as testing
             done at time of freezing meets standard criteria)

          -  Others as indicated by FDA-approved protocol

        Exclusion Criteria:

          -  Any contraindication to progesterone therapy

          -  BMI > 38 kg/m2

          -  Clinically significant gynecologic pathology (for example: submucosal fibroids,
             abnormal uterine cavity, or others)

          -  History of more than 1 failed fresh IVF cycles

          -  More than 2 consecutive clinical miscarriages (gestational sac observed on ultrasound)

          -  Others as indicated by FDA-approved protocol
Clinical trial NCT00105547 (phase 3, status: completed)
Conditions: alzheimer disease, dementia
ICD codes: G30.8, G30.9, G30.0, G30.1, G31.09, G31.83, F01.50, F01.51, F03.90, F03.91, F18.17
Drugs: mpc-7869, mpc-7869
SMILES: C[C@@H](C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1, C[C@@H](C(O)=O)C1=CC(F)=C(C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Have had a diagnosis of probable Alzheimer's disease.

          -  Men or women ages 55 years or greater and living in the community at the time of
             enrollment (i.e., not living in a rest home or nursing care facility).

          -  Signed the subject Informed Consent Form and is willing and able to participate for
             the duration of the study.

          -  Ability to read and understand English or Spanish to ensure compliance with cognitive
             testing and study visit procedures.

          -  Female subjects must be surgically sterile or postmenopausal for > 1 year.

          -  Subjects currently taking approved medication for Alzheimer's disease for at least six
             months prior to day 1 may be enrolled.

          -  Subjects must have a reliable caregiver who can read, understand and speak English or
             Spanish.

        Exclusion Criteria:

          -  Current evidence of other causes of dementia.

          -  History or evidence of, active malignancy, except for basal cell carcinoma or squamous
             cell carcinoma of the skin, within the 24 months prior to entry. Men with prostate
             cancer may be enrolled at the discretion of the sponsor.

          -  Chronic or acute renal, hepatic or metabolic disorder.

          -  Use of any investigational therapy within 30 days, or 5 half-lives, whichever is
             longer, and/or use of AD immunotherapy prior to screening.

          -  Major surgery and related complications not resolved within 12 weeks prior to Day 1.
Clinical trial NCT00326300 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: methylphenidate hydrochloride extended-release tablets
SMILES: COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Investigator determined diagnosis of ADHD as defined by the Diagnostic and Statistical
             Manual of Mental Disorders Fourth Edition (DSM-IV) criteria with symptomatology from
             childhood to adulthood, symptoms present before age seven years and continue to meet
             full DSM-IV criteria at time of assessment

          -  Diagnosis confirmed by the Adult ADHD Clinical Diagnostic Scale (ACDS) at Baseline and
             Adult ADHD Investigator Symptom Rating Scale (AISRS) score of 24 or greater as
             determined by the Investigator at Baseline

          -  Global Assessment of Functioning (GAF) Scale score of 41 to 60, inclusive, at Baseline

          -  Minimum weight of 100 lbs (45.4 kg) at Screening

          -  Negative urine drug test at the Screening and Baseline Visits when tested for drugs of
             abuse

        Exclusion Criteria:

          -  Known to be non-responders to methylphenidate or other stimulants for the treatment of
             ADHD

          -  History of allergy, sensitivity or contraindication to methylphenidate or components
             of methylphenidate HCl extended-release tablets

          -  Coexisting medical condition or taking concomitant medication that would interfere
             with safe administration of methylphenidate in the Investigator's opinion

          -  Known structural cardiac abnormality

          -  Diagnosis of or family history of Tourette's syndrome, or motor or verbal tics

          -  History of seizures or a seizure disorder other than febrile seizures in childhood

          -  Glaucoma

          -  Uncontrolled hyperthyroidism or hypothyroidism
Clinical trial NCT01204398 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: telmisartan+amlodipine fixed dose combination
SMILES: CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion criteria:

          1. Aged at least 18 years at the date of signing the consent form

          2. For treatment-naïve patients: hypertension defined by a mean seated diastolic blood
             pressure (DBP) equal or more than 100 mmHg measured by manual cuff sphygmomanometry at
             visit 1 and 2; For pretreatment patients: hypertension defined by a mean seated
             diastolic blood pressure equal or more than 90 mmHg at visit 1 and equal or more than
             100 mmHg at visit 2 measured by manual cuff sphygmomanometry

          3. 24-hour mean diastolic blood pressure equal or more than 85 mmHg at baseline
             Ambulatory Blood Pressure Monitoring

        Exclusion criteria:

          1. mean seated systolic blood pressure equal or more than 200 mmHg and/or mean seated
             diastolic blood pressure equal or more than 120 mmHg

          2. any clinically significant hepatic impairment

          3. severe renal impairment

          4. bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or
             post-renal transplant

          5. current treatment with any antihypertensive agents, whether or not prescribed for this
             indication, that cannot be safely stopped

          6. other conditions or situations that could put potential participants at unacceptable
             risk due to participation in this study
Clinical trial NCT00557245 (phase 3, status: completed)
Conditions: hiv-1 infections, hiv infections
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4, Z21
Drugs: tenofovir disoproxil fumarate (tdf), emtricitabine/tenofovir disoproxil fumarate (ftc/tdf), placebo
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria for HIV-1 uninfected partner:

          -  Partner within an HIV-1 discordant heterosexual relationship

          -  One partner meets study eligibility for HIV-1 uninfected study participant and the
             other partner meets study eligibility criteria for HIV-1 infected participant

          -  Plan to remain in the relationship for the duration of the study period

          -  Adequate renal, hepatic & hematologic function

          -  Negative Hepatitis B surface antigen test

          -  Willing and able to provide written informed consent & locator information

        Exclusion Criteria for HIV-1 uninfected partner:

          -  Current pregnancy, or planning to become pregnant during the study period

          -  Currently breastfeeding

          -  Concurrent enrollment in another HIV-1 vaccine or prevention trial

          -  Receiving ongoing antiretroviral therapy

          -  Repeated positive urine dipstick tests for glycosuria or proteinuria

          -  Active and serious infections

          -  History of pathological bone fractures not related to trauma

        Inclusion Criteria for HIV-1 infected partner:

          -  Partner within an HIV-1 discordant heterosexual relationship

          -  One partner meets study eligibility for HIV-1 uninfected study participant and the
             other partner meets study eligibility criteria for HIV-1 infected participant

          -  HIV-1 infected based on positive EIA

          -  No history of any clinical AIDS-defining diagnoses

          -  Plan to remain in the relationship for the duration of the study period

          -  Willing and able to provide written informed consent & locator information

        Exclusion Criteria for HIV-1 infected partner:

          -  Current use of antiretroviral therapy

          -  Concurrent enrollment in another HIV-1 treatment trial
Clinical trial NCT00237237 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  On a stable dose of metformin as defined by the protocol

          -  Blood glucose criteria must be met

          -  Body mass index (BMI) in the range 22-45

        Exclusion Criteria:

          -  History of type 1 diabetes

          -  Pregnancy or lactation

          -  Evidence of significant diabetic complications

          -  Serious cardiovascular events within the past 6 months

          -  Laboratory value abnormalities as defined by the protocol

          -  Known sensitivity to pioglitazone

          -  Other protocol-defined exclusion criteria may apply
Clinical trial NCT00518882 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: liraglutide, exenatide
SMILES: CN(C)C(=N)NC(N)=N, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Stable treatment with Oral Anti-Diabetic Drugs (metformin, sulphonylurea or a
             combination of both) for at least 3 months at the discretion of the Investigator

          -  HbA1C equal to or greater than 7.0% and equal to or lower than 11.0%

          -  Body Mass Index (BMI) equal to or lower than 45.0 kg/m2

        Exclusion Criteria:

          -  Previous treatment with insulin

          -  Treatment with any anti-diabetic drug other than metformin and sulphonylurea

          -  Any previous exposure to exenatide or liraglutide

          -  Impaired liver or/and renal function

          -  History of any significant cardiac events

          -  Known retinopathy or maculopathy requiring acute treatment

          -  Recurrent major hypoglycaemia or hypoglycaemic unawareness
Clinical trial NCT00256776 (phase 3, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: velcade (bortezomib), thalidomide, dexamethasone
SMILES: CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female ≥18 years-of-age

          -  Multiple myeloma with evaluable disease

          -  Relapsing or having a progressive disease

          -  Karnofsky performance status > 50 %

          -  Life expectancy of at least 3 months

          -  Female of child-bearing potential must have a method of birth control and a negative
             serum or urine beta--human chorionic gonadotropin (β-HCG) pregnancy test at screening
             and all through the study

          -  Male must use contraception

          -  Voluntary written informed consent

        Exclusion Criteria:

          -  Non-secretory multiple myeloma

          -  Platelet count < 40,000 X 10^9/L

          -  Absolute neutrophil count <1.0 X 10^9/L

          -  Creatinine clearance <30 mL/minute

          -  Peripheral neuropathy >= Grade 2

          -  Seropositive for HIV, or active hepatitis A, B or C infection

          -  Pregnant or breastfeeding female

          -  Patient has hypersensitivity to bortezomib, boron or mannitol

          -  Other investigational drugs

          -  Serious medical or psychiatric illness

          -  Previous or concurrent malignancies at other sites

          -  Poorly controlled hypertension, uncontrolled or severe cardiovascular disease or
             uncontrolled diabetes mellitus